​9 Meters Biopharma (NMTR) Appoints Michael Rice to Board of Directors

9 Meters Biopharma, Inc. (NASDAQ: NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the Company has appointed Michael Rice to its board of directors.

Mr. Rice is the president and co-founder of LifeSci Advisors, a life sciences investor relations consultancy, and the co-founder of LifeSci Capital, a research-driven investment bank. Previously, Michael was the co-head of health care investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael was also a Managing Director at ThinkEquity Partners where he was responsible for managing Healthcare Capital Markets, which included structuring and executing numerous transactions, many of which were firsts at ThinkEquity. Prior to that, Michael served as a Managing Director at Bank of America serving large hedge funds and private equity healthcare funds and earlier, he was a Managing Director at JPMorgan/Hambrecht & Quist.

"We are thrilled to add Mike's seasoned perspective and trusted guidance to the board," said Dr. Mark Sirgo, chairman of the board of directors of 9 Meters. "Mike's long history of serving emerging biopharmaceutical companies along with his ongoing capital markets knowledge will be invaluable to 9 Meters as the company drives its clinical programs in celiac and short bowel disease towards commercialization."

Mr. Rice added, "I have great respect for the 9 Meters team's work to serve people living with serious gastrointestinal diseases, and I place my utmost confidence in the science and corporate leadership underlying the company's growth strategy. I look forwarded in helping to guide the company behind their strategy to become a major player in the GI space."

You May Also Be Interested In

• FirstEnergy Corp. (FE) PT Raised to $35 at BofA Securities
• Addus HomeCare (ADUS) Comments on Final Department of Health and Human Services Rule
• CEL-SCI Corp (CVM) Appoints Mario Gobbo to Its Board